CUSIP: 761640101
Q4 2016 13F Holders as of 31 Dec 2016
-
Type / Class
-
Equity / COM
-
Total 13F shares
-
22,544,248
-
Share change
-
-7,131,627
-
Total reported value
-
$3,197,000
-
Price per share
-
$0.14
-
Number of holders
-
26
-
Value change
-
-$1,019,680
-
Number of buys
-
7
-
Number of sells
-
9
Quarterly Holders Quick Answers
What is CUSIP 761640101?
CUSIP 761640101 identifies RNN - REXAHN PHARMACEUTICALS INC - COM in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
-
Newer quarter:
Q1 2017
-
Previous quarter:
Q3 2016
Recent filing periods for CUSIP 761640101:
Institutional Holders of REXAHN PHARMACEUTICALS INC - COM (RNN) as of Q4 2016
As of 31 Dec 2016,
REXAHN PHARMACEUTICALS INC - COM (RNN) was held by
26 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
22,544,248 shares.
The largest 10 holders included
SABBY MANAGEMENT, LLC, Anson Funds Management LP, RENAISSANCE TECHNOLOGIES LLC, VANGUARD GROUP INC, GEODE CAPITAL MANAGEMENT, LLC, BlackRock Institutional Trust Company, N.A., NORTHERN TRUST CORP, HUDSON VALLEY INVESTMENT ADVISORS INC /ADV, Northeast Financial Consultants Inc, and Bank of New York Mellon Corp.
This page lists
26
institutional shareholders reporting positions in this security
for the Q4 2016 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.